The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans
Open accessAbstract
Amyloid β (Aβ) peptides are proteolytic products from amyloid precursor protein (APP) and are thought to play a role in Alzheimer disease (AD) pathogenesis. While much is known about molecular mechanisms underlying cerebral Aβ accumulation in familial AD, less is known about the cause(s) of brain amyloidosis in sporadic disease. Animal and postmortem studies suggest that Aβ secretion can be up-regulated in response to hypoxia. We employed a new technology (Single Molecule Arrays, SiMoA) capable of ultrasensitive protein measurements and developed a novel assay to look for changes in serum Aβ42 concentration in 25 resuscitated patients with severe hypoxia due to cardiac arrest. After a lag period of 10 or more hours, very clear serum Aβ42 elevations were observed in all patients. Elevations ranged from approximately 80% to over 70-fold, with most elevations in the range of 3-10-fold (average approximately 7-fold). The magnitude of the increase correlated with clinical outcome. These data provide the first direct evidence in living humans that ischemia acutely increases Aβ levels in blood. The results point to the possibility that hypoxia may play a role in the amyloidogenic process of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale
JENNETT, B. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92830-5 · Cited by 7,501 · cited 1×
“Patient outcome was assessed using the Glasgow-Pittsburgh cerebral performance category (CPC) scale at discharge from the intensive care unit and 6 months later [15].”
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationYaffe, K., Laffan, A. M., Harrison, S. L., Redline, S., Spira, A. P., Ensrud, K. E., Ancoli-Israel, S., & Stone, K. L. (2011) · JAMA · doi:10.1001/jama.2011.1115 · Cited by 1,137
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557
Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
Li, J., Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., & Zhou, H. D. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7a4 · Cited by 367
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
Self-citationOligemic Hypoperfusion Differentially Affects Tau and Amyloid-β
Koike, M. A., Green, K. N., Blurton-Jones, M., & LaFerla, F. M. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090750 · Cited by 130
Homocysteine and holotranscobalamin and the risk of Alzheimer disease: A longitudinal study
Hooshmand, B., Solomon, A., Kåreholt, I., Leiviskä, J., Rusanen, M., Ahtiluoto, S., Winblad, B., Laatikainen, T., Soininen, H., & Kivipelto, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f88162 · Cited by 122
Guo, X., Pantoni, L., Simoni, M., Bengtsson, C., Björkelund, C., Lissner, L., Gustafson, D., & Skoog, I. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.129700 · Cited by 73
Cited by
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citationKelley, S. O., Mirkin, C. A., Walt, D. R., Ismagilov, R. F., Toner, M., & Sargent, E. H. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.261 · Cited by 398
Blood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Neurovascular Unit Dysfunction and Neurodegenerative Disorders
Yu, X., Ji, C., & Shao, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00334 · Cited by 244
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
“Also in humans it was found that oxidative stress induced by hypoxia due to cardiac arrest increased serum A levels [281] suggesting that the machinery that generates this peptide is upregulated under pro-oxidative stress conditions in a wide range of disease models affecting various regions of the brain.”
BackgroundAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
Brand, A. L., Lawler, P. E., Bollinger, J. G., Li, Y., Schindler, S. E., Li, M., Lopez, S., Ovod, V., Nakamura, A., Shaw, L. M., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01117-1 · Cited by 151
Self-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Self-citationAn Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid-β
Palmer, J. C., Barker, R., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111760 · Cited by 110
Mondello, S., Kobeissy, F., Vestri, A., Hayes, R. L., Kochanek, P. M., & Berger, R. P. (2016) · Scientific Reports · doi:10.1038/srep28203 · Cited by 110
“Subdural hemorrhage 17 (38) 10 (53) 1 (17) 6 (30)”
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Self-citationAlexander, C., Li, T., Hattori, Y., Chiu, D., Frost, G. R., Jonas, L., Liu, C., Anderson, C. J., Wong, E., Park, L., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01676-7 · Cited by 64
Reduced Cardiovascular Functions in Patients with Alzheimer’s Disease
Jin, W.-S., Bu, X.-L., Wang, Y.-R., Li, L., Li, W.-W., Liu, Y.-H., Zhu, C., Yao, X.-Q., Chen, Y., Gao, C.-Y., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170088 · Cited by 27
Metadata
- Authors
- Zetterberg, H., Mörtberg, E., Song, L., Chang, L., Provuncher, G. K., Patel, P. P., Ferrell, E., Fournier, D. R., Kan, C. W., Campbell, T. G., Meyer, R., Rivnak, A. J., Pink, B. A., Minnehan, K. A., Piech, T., Rissin, D. M., Duffy, D. C., Rubertsson, S., Wilson, D. H., & Blennow, K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-12-14
- Volume
- 6
- Issue
- 12
- Pages
- e28263
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2103273331
- Cited by
- 173
- References
- 10
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.